Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune response to 4th dose booster with mRNA-1273 in previously CoronaVac + ChAdOx-1 or BNT162b2 vaccinated individuals
TCTR20220205002Recruiting
- Sponsor
- Thammasat University Hospital
- Start
- Jan 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Trial of elasomeran in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Thammasat University Hospital. Primary endpoint: Immune response to 4th dose mRNA-1273 booster. Started Jan 2022; status: recruiting.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20220205002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20220205002.